文献速递急性肾损伤慢性肾脏病肾血管病与高血压

门诊急性肾损伤时尿液生物标志物与后续肾功能恢复的关联:SPRINT研究

Associations of Urine Biomarkers During Ambulatory Acute Kidney Injury With Subsequent Recovery in Kidney Function: Findings From the SPRINT Study.
PubMed 文献 · Am J Kidney Dis · 2025-04-21

本研究基于SPRINT试验中652例在门诊降压治疗期间发生急性肾损伤(AKI)的参与者,分析基线及AKI检出时8种尿液生物标志物与12个月时eGFR恢复不足50%的关联。结果显示,反映肾小球损伤和肾小管功能障碍的尿液生物标志物与eGFR不恢复相关,且关联因随机治疗臂而异。

要点

  • 门诊AKI时尿液白蛋白肌酐比升高与标准降压臂eGFR不恢复相关。
  • 强化降压臂中,尿液α-1微球蛋白肌酐比升高和表皮生长因子肌酐比降低与eGFR不恢复相关。
  • 尿液生物标志物或有助于区分门诊AKI后肾功能是否恢复。

核心结论

  • 在降压治疗试验中发生门诊AKI的成人中,反映肾小球损伤和肾小管功能障碍的尿液生物标志物可能有助于区分肾功能后续是否恢复。

研究设计与样本

  • SPRINT试验参与者的纵向分析,纳入652例在1年或2年访视时检出门诊AKI(血清肌酐较基线升高≥0.3mg/dL)的参与者。

主要发现

  • 平均年龄70±10岁,基线eGFR为62±25mL/min/1.73m2,门诊AKI时eGFR为42±12mL/min/1.73m2。
  • 标准降压臂中,尿液白蛋白肌酐比每升高1个标准差,eGFR不恢复的OR为1.72(95%CI 1.10-2.70);表皮生长因子肌酐比每升高1个标准差,OR为0.46(95%CI 0.26-0.79)。
  • 强化降压臂中,尿液α-1微球蛋白肌酐比每升高1个标准差,OR为1.45(95%CI 1.09-1.92);表皮生长因子肌酐比每升高1个标准差,OR为0.62(95%CI 0.46-0.83);肾损伤分子-1肌酐比每升高1个标准差,OR为0.75(95%CI 0.59-0.96)。

临床怎么用

  • 在门诊发现血清肌酐升高时,可考虑检测尿液生物标志物以辅助判断肾功能恢复可能性。

局限性

  • 排除了糖尿病和蛋白尿>1g/d的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Serum creatinine elevations in the ambulatory setting frequently occur during antihypertensive treatment and complicate clinical management, but few tools are available to distinguish whether kidney function will recover in this setting. This study evaluated whether urine biomarkers of glomerular and tubular health are associated with subsequent recovery of estimated glomerular filtration rate (eGFR) after acute kidney injury (AKI) has occurred in the ambulatory setting during blood pressure (BP) treatment. STUDY DESIGN: Longitudinal analysis of clinical trial participants. SETTING & PARTICIPANTS: 652 participants in SPRINT (the Systolic Blood Pressure Intervention Trial) in whom AKI developed in the ambulatory setting, defined as an increase in serum creatinine of≥0.3mg/dL from baseline detected at the 1-year or 2-year study visit. EXPOSURE: Eight urine biomarkers indexed to urine creatinine (Cr) measured at baseline and at the study visit when ambulatory AKI was detected. OUTCOME: <50% recovery in eGFR ("nonrecovery") at 12 months. ANALYTICAL APPROACH: Multivariable logistic regression models, stratified by randomization arm, to evaluate biomarker associations with the odds of nonrecovery of eGFR. RESULTS: Mean age was 70±10 years; eGFRs were 62±25mL/min/1.73m2 at baseline and 42±12mL/min/1.73m2 at the time of ambulatory AKI. Among biomarkers measured at the time ambulatory AKI was detected, higher urine albumin-Cr ratio (OR per 1-standard deviation higher, 1.72; 95% CI, 1.10-2.70) and lower epidermal growth factor/Cr (OR, 0.46; 95% CI, 0.26-0.79) were associated with nonrecovery of eGFR in the standard BP treatment arm; higher urine α-1 microglobulin-Cr ratio (OR, 1.45; 1.09-1.92), lower epidermal growth factor Cr ratio (OR, 0.62; 95% CI, 0.46-0.83), and lower kidney injury molecule-1-Cr ratio (OR, 0.75; 95% CI, 0.59-0.96) were associated with nonrecovery of eGFR in the intensive BP treatment arm. LIMITATIONS: Persons with diabetes and proteinuria>1g/d were excluded. CONCLUSIONS: Among adults enrolled in a BP treatment trial who experienced ambulatory AKI, urine biomarkers reflecting glomerular injury and tubular dysfunction may help to distinguish whether kidney function will subsequently recover. PLAIN-LANGUAGE SUMMARY: Increases in serum creatinine concentration can occur when treating hypertension and complicate clinical management, but there are few tools available to distinguish whether an individual's kidney function will subsequently recover. In this study, we investigated the association of kidney biomarkers measured in the urine with subsequent kidney function among individuals in the outpatient setting in whom an increase in serum creatinine occurs. We found that biomarkers reflecting worse glomerular injury and tubular dysfunction are associated with the risk of an individual's kidney function not recovering. These results suggest that a broader assessment of kidney health when serum creatinine increases in the outpatient setting may help distinguish subsequent trajectories in kidney function.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Ascher SB, Katz R, Estrella MM, et al. Associations of Urine Biomarkers During Ambulatory Acute Kidney Injury With Subsequent Recovery in Kidney Function: Findings From the SPRINT Study. Am J Kidney Dis. 2025. PMID: 40268226. doi:10.1053/j.ajkd.2025.02.607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。